SARS Coronavirus Detection by Nitsche, Andreas et al.
SARS Coronavirus
Detection 
Andreas Nitsche,* Brunhilde Schweiger,* 
Heinz Ellerbrok,* Matthias Niedrig,* 
and Georg Pauli* 
We developed a set of three real-time reverse tran-
scription–polymerase chain reaction (PCR) assays that
amplify three different regions of the SARS-associated
coronavirus (SARS-CoV), can be run in parallel or in a sin-
gle tube, and can detect <10 genome equivalents of SARS-
CoV. The assays consider all currently available
SARS-CoV sequences and are optimized for two promi-
nent real-time PCR platforms.
The Study
Recently, a new coronavirus was identified as the
suspected causative agent of an increased number of
atypical pneumonia cases reported from Hong Kong,
Singapore, Vietnam, and Canada (1–4). Subsequent
publications demonstrated that this new coronavirus was
detectable in patients with severe acute respiratory
syndrome (SARS) (5,6), classified according to the World
Health Organization’s case definition (7). During the first
6 months of 2003, a total of 8,422 patients were affected.
This fact, together with the reappearance of the SARS-
associated coronavirus (SARS-CoV) in China in late 2003,
makes it clear that rapid and reliable diagnostic tools are
essential for accurate disease reporting and subsequent
disease management.
Because a defined treatment program and vaccination
strategy are lacking, the main strategy to counteract the
spread of this emerging virus is timely identification and
isolation of infected persons. SARS patients’typical initial
symptoms include fever, cough, and headache, similar to
many acute viral respiratory infections. Therefore,
molecular-based diagnostic methods are applied to rapidly
identify SARS-CoV–infected persons. Recently, nested
and real-time reverse transcription–polymerase chain
reaction (RT-PCR) assays to detect SARS-CoV have been
published (5,8). These assays—the first tools to detect
SARS-CoV in patients with SARS—were based on the
short stretches of viral sequence identified as the RNA-
directed RNA polymerase of a new microbe.
Subsequently, sequences from several SARS-CoV iso-
lates were determined, and all of these sequences were
closely related, as would be expected during the clustered
outbreaks in 2003. However, the genomes of RNAviruses,
including those of coronaviruses, tend to vary over time
and with location (9–12). Recently, the sequence variations
of SARS-CoV during the first epidemic phases in China in
2003 were reported. The neutral mutation rate for SARS-
CoV was almost constant and similar to that of known
RNA viruses; the S protein, responsible for virus-host
receptor recognition, displayed the most extensive amino
acid changes (13). In addition, the sequence analysis of
isolates from recent SARS patients in China in 2004 has
shown that 98.8%–99.4% of the 3,768 bases of S gene,
99% of 658 bases of M gene, and 99% of 1,068 bases of N
gene are isogenous with those submitted to public databas-
es, which date back to the first epidemic in spring 2003
(14). However, even these minimal changes could render
existing PCR assays ineffective should SARS-CoV
reemerge (15).
To improve the ability to detect SARS-CoV safely and
reduce the risk of eliciting false-negative results caused by
genome sequence variations, we established three
individual real-time RT-PCR assays. Target sequences
were chosen by using the following criteria: 1) the regions
are distributed over the whole genome, including the
nonstructural polyprotein 1a and 1ab genes and the spike
glycoprotein gene (Table 1); 2) the regions are highly
conserved among the 89, 90, and 100 respective sequences
available in public sequence databases; 3) the regions are
suitable for the design of a real-time RT-PCR assay; and 4)
the designed primers, 5′-nuclease probes, and amplicons
displayed no considerable homology to other viruses,
including human CoV OC43 and 229E in BLAST searches
(available from http://www.ncbi.nlm.nih.gov/BLAST/). 
These assays were based on the fluorogenic oligoprobe
chemistry, which uses the 5′-exonuclease activity of the
DNA polymerase to generate a more specific signal than
that produced by the use of SYBR Green I (8). The real-
time RT-PCR assays were successfully run on the Applied
Biosystems real-time PCR systems (SDS7700 and
SDS7000; Applied Biosystems, Foster City, CA) as well as
on the Roche LightCycler (Roche Diagnostics GmbH,
Mannheim, Germany). All assays were designed as one-
step RT-PCR reactions to be run under identical conditions
on the respective PCR platform. This system allowed the
simultaneous detection of different SARS-CoV regions in
a single PCR run. Moreover, we could combine the three
assays in a single tube, which might be important when
clinical material is limited. Finally, the assays were com-
pared to the 5′-nuclease assay published recently (5) and to
a commercially available real-time PCR kit (Real-Art
HPA-Coronavirus LC RT PCR Reagents, Artus GmbH,
Hamburg, Germany).
After optimization of primer and 5′-nuclease probe
concentration and annealing temperature, reaction condi-
tions for our 5′-nuclease assay were as follows. For the RT-
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each 25-µL reaction contained 12.5 µL of 2xQuantiTect
Probe RT-PCR Master Mix (Qiagen, Hilden, Germany), 10
pmol of each primer, 3 pmol of 5′-nuclease probe, and 0.25
µL of QuantiTect Probe RT Mix. RNase-free water was
added up to 23 µL, and 2 µL of RNA was used. Cycling
conditions were 30 min at 50°C for RT reaction, 15 min at
95°C for inactivation of RT, activation of the Taq DNA
polymerase, and cDNA denaturation, followed by 45
cycles of 15 s at 95°C and 30 s at 60°C. Total running time
was 140 min.
For LightCycler RT-PCR reactions, each 20-µL reac-
tion included 7.5 µL of 2.7xLightCycler RNA Master
Hybridization Probes mix (Roche Diagnostics GmbH), 10
pmol of each primer, 3 pmol of the 5′-nuclease probe, and
1.3 µL Mn (OAc)2 (50 mmol/L). RNase-free water was
added up to 18 µL, and 2 µL of RNA was used. Cycling
conditions were 20 min at 55°C for the RT reaction, 30 s at
95°C for initial denaturation, followed by 45 cycles of 1 s
at 95°C, 10 s at 55°C, and 10 s at 72°C. Total running time
was 55 min. The combined assays were set up by adding
all primers and probes in the same concentration; the
amount of water was reduced accordingly. Protocols are
also available from the Robert Koch-Institut homepage
(www.rki.de/INFEKT/SARS/PCRPROTOCOL.PDF).
The human L13 gene and the human cyclophilin gene (16)
were amplified under identical reaction conditions as the
SARS-CoV–specific assays on the ABI platforms and the
LightCycler, respectively, to act as amplification controls.
To evaluate the sensitivity of the SARS-CoV–specific
assays, RT-PCRs were performed repeatedly on serial dilu-
tions of RNA extracted with the Viral RNA Kit (Qiagen)
from cultured SARS-CoV with defined amounts of
genome equivalents (GE) by using the international stan-
dard of the European Network for the Diagnostics of
Imported Viral Diseases (ENIVD), distributed through the
Robert Koch-Institut (available from: http://www.
rki.de/INFEKT/SARS/DATASHEET.PDF). Results are
shown in Table 2. Detection limits of the three new assays
were <10 GE. Comparison of the threshold cycle (CT) val-
ues showed that the new assays were at least as sensitive
as the previously described assays (5,8) and the commer-
cially available kit. When we combined the assays in a sin-
gle tube targeting three different regions on the same RNA
template, the CT was reduced by 1 to 2 cycles (SDS7700),
which suggests either that sensitivity was unchanged or,
when there was an increase, that it was attributable to the
combination of all three signals (LightCycler). Subsequent
agarose gel analysis during optimization steps of the PCR
confirmed the simultaneous amplification of the three RT-
PCR products (Figure, online only; available from:
http://www.cdc.gov/ncidod/EID/vol10no7/03-0678-G.htm).
Using the single or combined assays, we analyzed 27
bronchoalveolar-lavage fluid samples from 19 suspected
SARS case-patients and 8 probable SARS patients
(according to the Robert Koch-Institut case definition,
available from http://www.rki.de/INFEKT/SARS/AOLG-
FALLDEF-ARSUU.PDF). All samples were positive for
L13 and cyclophilin control sequences when amplified in
parallel. In agreement with the previously published assay
results (5), SARS-CoV was detectable in three samples
from eight probable SARS patients, without explicit differ-
ences in the CT value of individual assays when the single
or combined assays were used. These patients were
seropositive and are regarded as confirmed SARS patients.
Respiratory samples and stool samples taken 8 days later
from the remaining 5 probable patients as well as the 19
persons with suspected disease were negative by RT-PCR.
Moreover, these patients remained seronegative and are
regarded as unconfirmed SARS patients. In addition, 35
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Table 1. Primers and 5′-nuclease probes of the three SARS coronavirus–specific assays
a 
Primer/probe  Primer/probe sequence 
Oligonucleotide 
orientation 
Nucleotide 
position
b  Tm (°C)
c 
  NS pp1a (133 bp)
d       
pp1a F  GCCgTAgTgTCAgTATCATCACC  S  4609–4631  56.6 
pp1a R  AATAggACCAATCTCTgTAAgAgCC  A  4741–4717  56.7 
pp1a TM  F-TCACTTCgTCATCAAAgACATC XT gAggAgC p  S  4661–4690  66.2 
  NS pp1ab (88 bp)
d       
NS F  TTTTgTTgTTTCAACTggATACCAT  S  14387–411  57.0 
NS R  GAAACTgAgACgCgAgCTATgT  A  14474–453  57.3 
NS TM  F-CATCCTgATTATgTACgACTCCTAAC XT CACgAA p  A  14445–413  64.4 
  Surface spike glycoprotein (79 bp)
d       
SS GP F  gAggTCTTTTATTgAggACTTgCTC  S  23879–903  57.1 
SS GP R  gCATTCgCCATATTgCTTCAT  A  23957–937  57.3 
SS GP TM  F-AAgCCAgCATCAgCgAgTgTCACCTTA XT p  A  23935–908  66.7 
aSARS, severe acute respiratory syndrome; S, sense; A, antisense; F, 6-carboxyfluorescein attached to 5´-terminus (FAM); T, 5-
carboxytetramethylrhodamine (5-TAMRA) attached to 5-ethylamino-dThymidin; NS, nonstructural; pp1ab, polyprotein 1ab gene; Tm, melting temperature; 
TM, TaqMan. 
bBased on AY274119 isolate TOR2.  
cThermodynamic Tm. All oligonucleotides were synthesized by TIB MOLBIOL, Berlin. 
dAmplicon length. serum samples from patients with SARS-CoV infection
obtained 1–52 days after disease onset were analyzed.
Between 20 and 1,000 GE/mL of SARS-CoV–specific
RNA was detected in 21 of 35 serum samples, even when
serum was obtained from patients 1 day after disease
onset. (A detailed description of this study will be pub-
lished later.)
Conclusions
None of the assays displayed cross-reactivity to clinical
samples containing human cDNAfrom blood; human CoV
229E; influenza viruses Aand B; parainfluenzaviruses 1, 2,
and 3; respiratory syncytial virus; rhinoviruses;
enteroviruses; adenoviruses 1–10; human metapneu-
movirus; Mycoplasma pneumoniae; or Chlamydia pneu-
moniae. For these pathogens, we obtained neither a
fluorescent signal nor an amplification product in subse-
quent agarose gel analysis (selection shown in online
Figure). Although we focused on a one-step RT-PCR to
decrease handling and total assay time, the three real-time
RT-PCR assays can also be performed as two-step RT-
PCR, including a separate cDNA synthesis step followed
by PCR, and then finally using appropriate ready-to-use
master mixes and the same cycling condition, omitting the
RT step.
The single assays and the combined assay were also
used in an external quality assessment to detect SARS-
CoV, organized by the ENIVD. All assays could detect
SARS-CoV in 7 of 11 samples with virus loads ranging
from 5x106 to 2x103 GE of two isolates of SARS-CoV per
milliliter sample without false-positive or false-negative
results. While the application of three single assays to
detect SARS-CoV leads to a higher reliability of negative
results, reflecting the negative outcome of three independ-
ent amplification reactions, it is a more expensive
approach than combining the assays.
In conclusion, the real-time RT-PCR assays we describe
provide a fast and reliable tool that can complement and
improve recently introduced techniques for SARS
diagnostics. Parallel amplification of two human reference
genes, L13 and cyclophilin, confirmed negative results in
clinical samples by demonstrating amplifiable RNA. The
separation of the control reaction was chosen to guarantee
the high sensitivity of the SARS-CoV detection of <10 GE
of SARS-CoV per reaction. An RT-PCR run is completed
in <1 h, depending on the real-time PCR platform. In cases
of small amounts of material or in an emergency situation
with a high throughput of samples, the three SARS-CoV–
specific assays can be combined into one RT-PCR reaction
without loss of sensitivity. Furthermore, as the ambiguous
diagnostic results in a hospital in Canada have recently
shown (17), targeting three different regions distributed
over the whole genome considerably reduces the risk for
false-negative results caused by virus sequence
modifications. 
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